{
    "clinical_study": {
        "@rank": "75697", 
        "arm_group": [
            {
                "arm_group_label": "Propaten", 
                "arm_group_type": "Active Comparator", 
                "description": "Artegraft\u00ae vs Gore\u00ae Propaten\u00ae. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care."
            }, 
            {
                "arm_group_label": "Artegraft", 
                "arm_group_type": "Active Comparator", 
                "description": "Artegraft\u00ae vs Gore\u00ae Propaten\u00ae. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care."
            }
        ], 
        "brief_summary": {
            "textblock": "Compare Artegraft and Propaten grafts for use in dialysis access to see if one performs\n      better than the other.  How long each one lasts until a complication arises or until the\n      graft is no longer used will be compared.\n\n      The study hypothesis is that the Artegraft, being an actual blood vessel, will work better\n      than the manufactured Propaten graft."
        }, 
        "brief_title": "Artegraft Versus Propaten Dialysis Grafts", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "ESRD", 
            "Renal Failure"
        ], 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "detailed_description": {
            "textblock": "Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring\n      hemodialysis will be randomized to receive one of these two grafts as part of their standard\n      care. Patients will be assessed at 2-3 weeks post-operatively and again at 6 and 12 months\n      for flow characteristics, dialysis adequacy and graft associated complications such as\n      stenosis, infection and thrombosis. Data on urea reduction ratio (URR), kinetic modeling\n      (Kt/V), and access flow (QB) will be collected at 3, 6, 9 and 12 months via phone call to\n      the hemodialysis center in order to evaluate patency and function.\n\n      Access complications (stenosis, thrombosis, infection) will be treated per our standard\n      protocol.  These data will be recorded and then primary, assisted primary and secondary\n      patency rates will be calculated and the graft arms compared using life table analysis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  > 18 years of age\n\n          -  Candidate for hemodialysis\n\n          -  Not a candidate for native AV fistula\n\n          -  In need of a new AV graft in the upper arm location\n\n          -  Artery and vein > 3mm.\n\n          -  Medically stable and have a life expectancy of \u2265 12 months\n\n          -  The patient or legal guardian understands the study and is willing to comply with the\n             requirements.\n\n        Exclusion Criteria:\n\n          -  < 18 years of age\n\n          -  Current history or within 6 months of IV drug abuse\n\n          -  Chronic hypotension (<100 mm systolic pressure) not responsive to treatment\n\n          -  Pregnant or lactating\n\n          -  Known hypercoagulable state\n\n          -  Requires only a revision of an existing graft\n\n          -  Receiving artery or vein is less than 3 mm in diameter at the time of implantation\n\n          -  Known axillary/subclavian occlusion or stenosis that has not been treated\n\n          -  Known or suspected systemic infection\n\n          -  Heparin sensitivity (known HIT)\n\n          -  Enrolled in another investigational study.\n\n          -  Subject has more than 1 graft in target limb."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02099344", 
            "org_study_id": "ABCA-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Propaten", 
                    "Artegraft"
                ], 
                "description": "Surgical placement of graft for hemodialysis access", 
                "intervention_name": "Artegraft", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Propaten", 
                    "Artegraft"
                ], 
                "description": "Surgical placement of graft for hemodialysis access", 
                "intervention_name": "Propaten", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "contact": {
                "email": "earl.s.schuman@kp.org", 
                "last_name": "Earl Schuman, MD", 
                "phone": "503-571-7373"
            }, 
            "facility": {
                "address": {
                    "city": "Portland", 
                    "country": "United States", 
                    "state": "Oregon", 
                    "zip": "97232"
                }, 
                "name": "Kaiser Permanente Northwest"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomized Study of the Artegraft vs Propaten Vascular Grafts for Renal Failure Patients Requiring Dialysis Access", 
        "overall_contact": {
            "email": "earl.s.schuman@kp.org", 
            "last_name": "Earl Schuman, MD", 
            "phone": "503-571-7373"
        }, 
        "overall_contact_backup": {
            "email": "kathleen.ann.arnold@kpchr.org", 
            "last_name": "Kathy Arnold, RN, BSN", 
            "phone": "503-571-3802"
        }, 
        "overall_official": {
            "affiliation": "Kaiser Permanente Northwest", 
            "last_name": "Earl Schuman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome will be determined by Kaplan-Meier life table analysis.  Patency determination will be from access creation until the first occlusion of the graft.", 
            "measure": "Primary Objective: The primary objective is to assess the primary, primary assisted and secondary patency rate of each graft", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02099344"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Complication incidence will be collected from the time of access creation until the graft fails and is abandoned.", 
            "measure": "Examine incidence of complications in patients receiving the Artegraft bovine graft vs. Gore Propaten graft", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "source": "Kaiser Permanente", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kaiser Permanente", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}